| Literature DB >> 20335956 |
Kin-Weng Kong1, Hock-Eng Khoo, K Nagendra Prasad, Amin Ismail, Chin-Ping Tan, Nor Fadilah Rajab.
Abstract
By-products derived from food processing are attractive source for their valuable bioactive components and color pigments. These by-products are useful for development as functional foods, nutraceuticals, food ingredients, additives, and also as cosmetic products. Lycopene is a bioactive red colored pigment naturally occurring in plants. Industrial by-products obtained from the plants are the good sources of lycopene. Interest in lycopene is increasing due to increasing evidence proving its preventive properties toward numerous diseases. In vitro, in vivo and ex vivo studies have demonstrated that lycopene-rich foods are inversely associated to diseases such as cancers, cardiovascular diseases, diabetes, and others. This paper also reviews the properties, absorption, transportation, and distribution of lycopene and its by-products in human body. The mechanism of action and interaction of lycopene with other bioactive compounds are also discussed, because these are the crucial features for beneficial role of lycopene. However, information on the effect of food processing on lycopene stability and availability was discussed for better understanding of its characteristics.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20335956 PMCID: PMC6263198 DOI: 10.3390/molecules15020959
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Physical properties of lycopene.
| Molecular formula | C40H56 |
| Molecular weight | 536.85 Da |
| Melting point | 172–175 ºC |
| Crystal form | Long red needles separate from a mixture of carbon disulfide and ethanol |
| Powder form | Dark reddish-brown |
| Solubility | Soluble in chloroform, hexane, benzene, carbon disulfide, acetone, petroleum ether and oil; |
| Insoluble in water, ethanol and methanol | |
| Stability | Sensitive to light, oxygen, high temperature, acids, catalyst and metal ions |
Source: Shi et al. [23].
Figure 1Molecular structures of lycopene isomers.
Plasma lycopene levels in people from different countries.
| References | Country | Plasma lycopene levels (µmol/L) | |
|---|---|---|---|
| Male | Female | ||
| [ | UK | - | 0.32 ± 0.12 |
| [ | USA | 0.82 ± 0.38 | 0.76 ± 0.32 |
| [ | France | 0.66 (0.18-1.47) | 0.66 (0.31-2.06) |
| Republic of Ireland | 0.73 (0.09-2.12) | 0.57 (0.09-0.65) | |
| The Netherland | 0.54 (0.08-1.72) | 0.53 (0.04-1.98) | |
| Spain | 0.53 (0.21-1.16) | 0.51 (0.07-1.72) | |
| Ireland | 0.30 ± 0.13 | 0.25 ± 0.11 | |
| [ | Italy (Varese/Turin) | 1.03 ± 0.43 | 0.90 ± 0.37 |
| Italy (Florence) | 1.01 ± 0.37 | 0.90 ± 0.36 | |
| Italy (Ragusa/Naples) | 1.29 ± 0.46 | 1.32 ± 0.46 | |
| Greece (Athens) | 0.90 ± 0.38 | 0.87 ± 0.47 | |
| Spain (Granada) | 0.69 ± 0.40 | 0.69 ± 0.33 | |
| Spain (Murcia) | 0.66 ± 0.30 | 0.74 ± 0.35 | |
| Northern Spain | 0.53 ± 0.31 | 0.43 ± 0.29 | |
| UK (vegetarians) | 0.98 ± 0.45 | 0.89 ± 0.44 | |
| UK (Cambridge) | 0.72 ± 0.30 | 0.77 ± 0.38 | |
| Germany (Potsdam) | 0.60 ± 0.30 | 0.69 ± 0.33 | |
| Germany (Heidelberg) | 0.62 ± 0.31 | 0.54 ± 0.25 | |
| The Netherlands | 0.54 ± 0.33 | 0.47 ± 0.26 | |
| Denmark | 0.58 ± 0.34 | 0.53 ± 0.29 | |
| Sweden (Malmö) | 0.46 ± 0.24 | 0.52 ± 0.27 | |
| Sweden (Umeå) | 0.56 ±0.37 | 0.44 ± 0.25 | |
| [ | Japan | 0.11 (0.04-0.33) | 0.20 (0.08-0.52) |
| [ | Thailand | 0.46 ± 0.33 | 0.74 ± 0.38 |
Figure 2Proposed structures of the metabolites detected.
Figure 3Three Possible Reactions of Carotenoids with Radical Species (R•).
Action of lycopene in improving the impairment of other diseases.
| Lycopene doses | Method | Impairment | Improvement | Lit. cited |
|---|---|---|---|---|
| 0.2 mg/kg b.w. daily | Cataract | Significant delayed in the onset and progression of galactose cataract and reduced the incidence of selenite cataract. | 145 | |
| 2.5, 5 and 10 mg/kg b.w. daily | Cognitive function | Significant improved in memory. | 143 | |
| 60 mg/kg b.w. daily | Lipid peroxidation injury | Significant reduced in the levels of serum TG and MDA, increase serum SOD activity, increase serum NO. | 146 | |
| 0.1, 0.5, 1, 2 g/kg b.w. daily | Swelling | Decreased swelling of the croton oil-induced ear. | 147 | |
| 0, 5 and 10 μg/mLcarried by liposomes | Inflammation of cells infected by rhinovirus or exposed to lipopolysaccharide | Reduced the release of interleukin-6 and interferon-gamma induced protein-10. | 148 | |
| 8 or 16 mg/kg/day by i.p. injection | Ovalbumin-induced inflammation | Significant inhibition of the infiltration of inflammatory immunocytes into the bronchoalveolar lavage. | 149 | |
| 2 mgtwice daily | Pre-eclampsia and intrauterinegrowth retardation | Significant reduced in pre-eclamsia incidence and intrauterine growth retardation in the lycopene group compare to placebo group. | 150 | |
| 9 mg/kg b.w. twice a day for 2 weeks | Chronic bacterial prostatitis | Significant decreased in bacterial growth and improvement of prostatic inflammation. | 151 | |
| 0.025–2 mg per 20 mg b.w. | X-ray radiation lesions | Moderate curative effect on the radiation lesions and increased survival rate | 152 |
Studies on lycopene from by-products.
| Country | By-products | References |
|---|---|---|
| Algeria | Tomato skin | 160 |
| Argentina | Tomato skin | 161 |
| Canada | Tomato skin | 162 |
| China, Canada | Tomato paste waste | 163 |
| China | Tomato paste waste | 164 |
| Tomato paste waste | 165 | |
| India | Mace ( | 166 |
| Tomato peels and seeds, tomato industrial waste | 167 | |
| Tomato skin | 20 | |
| Iraq | Tomato skin | 158 |
| Italy | Tomato peels and seeds | 168 |
| Tomato peels | 169 | |
| Hungary | Tomato pomace | 19 |
| Japan | Tomato skin | 18 |
| Portugal, Brazil | Tomato skin and seeds | 170 |
| Spain | Tomato peels | 171 |
| Taiwan | Tomato pulp waste | 172 |
| Turkey, Netherland | Tomato paste waste | 173 |
| USA | Tomato pomace | 174 |